In a post-marketing surveillance study, the efficacy and tolerability of memantine (Ebixa (R)) was examined in patients with moderate to severe Alzheimer's disease (AD). Patients were treated with memantine 20 mg/day for six months. Memantine's efficacy was evaluated using the Mini-Mental-State Examination (MMSE), the Nurses' Observation Scale for Geriatric Patients (NOS-GER) and the Explorations Module Dementia (EMD) scales, as well as by a global assessment by the physician. After six months of open label treatment with memantine, patients' cognitive function, ability to perform daily activities, and global performance have been clearly improved. Also. memantine showed an excellent tolerability profile. The results of this naturalistic study support the significant efficacy and tolerability of memantine that has been previously demonstrated in randomised, controlled clinical Alzheimer dementia trials.     «

In a post-marketing surveillance study, the efficacy and tolerability of memantine (Ebixa (R)) was examined in patients with moderate to severe Alzheimer's disease (AD). Patients were treated with memantine 20 mg/day for six months. Memantine's efficacy was evaluated using the Mini-Mental-State Examination (MMSE), the Nurses' Observation Scale for Geriatric Patients (NOS-GER) and the Explorations Module Dementia (EMD) scales, as well as by a global assessment by the physician. After six months o...     »